)

Virbac SA (VIRP) investor relations material
Virbac SA H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Revenue for H1 2025 reached €738.3 million, up 5.0% year-over-year, with 5.6% organic growth at constant rates and scope, and 2.2% M&A contribution from Sasaeah; strong performances in most regions except Pacific.
New CEO Paul Martingell appointed, emphasizing continuity and execution; Habib Ramdani returned to CFO and deputy CEO roles.
Strategic focus remains on innovation, acquisitions, and competitiveness, with a target of 20% EBIT adjusted margin by 2030.
Net income was €82.2 million, down from €94.9 million in H1 2024, mainly due to margin pressure, higher financial charges, and FX losses.
Integration of Sasaeah (Japan) and Mopsan (Turkey) progressing well, both exceeding revenue expectations.
Financial highlights
Adjusted EBIT for H1 2025 was €135 million (18.3% of revenue), down 2.4 points YoY at constant exchange rates, impacted by higher inventory write-offs, temporary production shutdowns, and FX.
Net debt increased to €201.4 million, mainly due to higher CapEx, seasonal working capital needs, and dividend payments.
CapEx nearly doubled YoY to €53.9 million, focused on major industrial investments and transformation projects.
Net cash flow generation was €97.4 million, down 16% from H1 2024, reflecting increased CapEx and working capital.
Net free cash flow was -€41.1 million, reflecting higher CapEx and working capital needs.
Outlook and guidance
Full-year 2025 guidance confirmed: revenue growth of 4%-6% at constant rates and scope, with Sasaeah adding 1 point; adjusted EBIT margin expected around 16%.
CapEx expected above €100 million for 2025 and 2026, supporting ongoing industrial projects.
Cash position projected to improve by €80 million in 2025, excluding acquisitions.
Moderate impact anticipated from US customs tariffs, with most US revenue shifting to local production.
Strategic target of 20% EBIT adjusted margin by 2030 reaffirmed.
Next Virbac SA earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
French Animal Health
Virbac is a French veterinary pharmaceutical company with multinational operations. The company focuses on developing, producing, and marketing a wide range of drugs and vaccines to improve the health and well-being of pets and livestock. Their product portfolio covers various areas, including parasitology, dermatology, dental care, antibiotics, and nutrition for animals. It is headquartered in Carros, France, and its shares are traded on the XPAR.
From a Small Clinic to a Global Giant
What would go on to become a global company and one of the largest companies in worldwide animal health was started as a veterinary office in a mall in Nice, France. Its founders, veterinarians Pierre-Richard Dick and Max Rombi sold the office after a few years and started to focus solely on medications and drugs for pets. This is something that helped Virbac establish itself, as most other similar companies at the time focused on livestock. During the 1970s, the company expanded by opening subsidiaries in several countries, and Virbac of today is a truly global company. Today, the company produces products and medications for both companion animals and livestock, and a large majority of its revenue is generated outside of France. Some other large companies operating in the sector include Zoetis and Elanco.
Pet Health
Their portfolio includes a variety of pharmaceuticals, vaccines, and nutritional supplements designed for both dogs and cats. Key product categories encompass flea and tick control, dental care, dermatology, and kidney health, along with a broad spectrum of vaccines to prevent common infectious diseases. Additionally, Virbac provides nutritional supplements that support overall pet wellness, aimed at reducing issues like joint health and digestion.
Products for Livestock
Virbac's product range in the livestock sector encompasses a comprehensive array of health solutions, targeting cattle, sheep, pigs, and poultry. Their portfolio includes vaccines and parasiticides, essential in controlling internal and external parasites that can affect animal health and productivity. Virbac also produces products for reproductive health and nutrition.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage